White & Case Advises Takeda on Agreement to Divest Select Non-Core Assets to Hasten for Approximately US$322 Million
1 min read
Global law firm White & Case LLP has advised Takeda Pharmaceutical Company Limited (Takeda) on an agreement to divest a portfolio of select non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co. Ltd. (Hasten) for approximately US$322 million.
Takeda is a leading global biopharmaceutical company headquartered in Japan that is primarily focused on five business areas: gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. Hasten is a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited.
White & Case previously advised Takeda on divestiture agreements in 2019 covering select over-the-counter and prescription pharmaceutical products in the Near East, Middle East and Africa (NEMEA), Russia, Georgia and a number of countries in the Commonwealth of Independent States, and in Latin America, Europe and Asia-Pacific during 2020.
The White & Case team that advised on the transaction was led by partners Michael Immordino and Leonardo Graffi (both Milan & London) and included partners Philip Trillmich, Monica Holden (both London), Vivian Tsoi (Shanghai) and Axel Schulz (Brussels), associates Caitlin Powell Gimpel (Chicago), Allison Gong (Beijing), Ajita Shukla (Washington, DC) and Tommaso Poli (Brussels) and lawyer Mariasole Maschio (Milan).
For more information please speak to your local media contact.